Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cell-Free Nucleic Acids | 2 | 2025 | 95 | 1.020 |
Why?
|
| Meningeal Neoplasms | 2 | 2025 | 69 | 0.920 |
Why?
|
| Circulating Tumor DNA | 2 | 2025 | 76 | 0.880 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2017 | 1339 | 0.730 |
Why?
|
| Biomarkers, Tumor | 7 | 2025 | 1661 | 0.710 |
Why?
|
| Lung Neoplasms | 7 | 2024 | 2368 | 0.700 |
Why?
|
| Carcinoma, Lobular | 3 | 2017 | 84 | 0.700 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2010 | 1077 | 0.570 |
Why?
|
| Chromosome Aberrations | 2 | 2010 | 350 | 0.550 |
Why?
|
| Gene Silencing | 2 | 2016 | 177 | 0.490 |
Why?
|
| Cadherins | 2 | 2016 | 180 | 0.470 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 147 | 0.460 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2016 | 129 | 0.450 |
Why?
|
| Breast Neoplasms | 6 | 2023 | 3158 | 0.430 |
Why?
|
| Paracrine Communication | 1 | 2014 | 32 | 0.430 |
Why?
|
| Gene Expression Profiling | 6 | 2016 | 1517 | 0.410 |
Why?
|
| Stromal Cells | 1 | 2014 | 151 | 0.400 |
Why?
|
| Exosomes | 1 | 2014 | 60 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 636 | 0.370 |
Why?
|
| Bronchi | 2 | 2009 | 225 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 1133 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2010 | 113 | 0.310 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 538 | 0.290 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 691 | 0.290 |
Why?
|
| Respiratory Mucosa | 1 | 2009 | 90 | 0.280 |
Why?
|
| Mutation | 6 | 2025 | 4266 | 0.280 |
Why?
|
| Genetic Markers | 1 | 2009 | 469 | 0.270 |
Why?
|
| Nucleic Acid Probes | 1 | 2007 | 1 | 0.270 |
Why?
|
| Poly A | 1 | 2007 | 20 | 0.260 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2007 | 41 | 0.260 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 505 | 0.260 |
Why?
|
| Neoplasms | 4 | 2023 | 3170 | 0.250 |
Why?
|
| Mammary Glands, Human | 2 | 2017 | 26 | 0.250 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 306 | 0.250 |
Why?
|
| DNA Mutational Analysis | 2 | 2025 | 543 | 0.240 |
Why?
|
| Artifacts | 1 | 2007 | 243 | 0.230 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 174 | 0.220 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2025 | 72 | 0.220 |
Why?
|
| Smoking | 1 | 2009 | 648 | 0.220 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2024 | 7 | 0.220 |
Why?
|
| Acrylamides | 1 | 2024 | 34 | 0.220 |
Why?
|
| Cell Line, Tumor | 5 | 2023 | 2756 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 538 | 0.210 |
Why?
|
| Aniline Compounds | 1 | 2024 | 62 | 0.210 |
Why?
|
| Ascitic Fluid | 1 | 2024 | 37 | 0.210 |
Why?
|
| Whole Genome Sequencing | 2 | 2023 | 109 | 0.210 |
Why?
|
| Female | 15 | 2025 | 48781 | 0.210 |
Why?
|
| Genetic Counseling | 1 | 2023 | 101 | 0.190 |
Why?
|
| Aged | 8 | 2025 | 20472 | 0.190 |
Why?
|
| Thymidine Phosphorylase | 1 | 2003 | 5 | 0.190 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 7072 | 0.190 |
Why?
|
| Peritoneal Neoplasms | 1 | 2024 | 184 | 0.190 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2023 | 40 | 0.180 |
Why?
|
| Neovascularization, Physiologic | 1 | 2003 | 140 | 0.180 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 96 | 0.180 |
Why?
|
| Humans | 22 | 2025 | 93613 | 0.180 |
Why?
|
| ErbB Receptors | 1 | 2024 | 506 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 398 | 0.170 |
Why?
|
| Stomach Neoplasms | 1 | 2024 | 308 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.160 |
Why?
|
| Genetic Therapy | 1 | 2003 | 365 | 0.160 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2023 | 190 | 0.160 |
Why?
|
| Middle Aged | 7 | 2025 | 27623 | 0.150 |
Why?
|
| Gene Amplification | 3 | 2021 | 140 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 302 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 572 | 0.140 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 280 | 0.130 |
Why?
|
| Male | 8 | 2025 | 44582 | 0.130 |
Why?
|
| Transcription Factor AP-2 | 1 | 2017 | 14 | 0.130 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2017 | 3 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 300 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 812 | 0.130 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 555 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 885 | 0.120 |
Why?
|
| Integrases | 1 | 2016 | 66 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2016 | 3500 | 0.120 |
Why?
|
| Quinolines | 1 | 2016 | 85 | 0.120 |
Why?
|
| Gene Editing | 1 | 2016 | 51 | 0.120 |
Why?
|
| Imidazoles | 1 | 2016 | 138 | 0.120 |
Why?
|
| Animals | 8 | 2023 | 28047 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 281 | 0.110 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2014 | 28 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 413 | 0.110 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 59 | 0.110 |
Why?
|
| Interferons | 1 | 2014 | 112 | 0.100 |
Why?
|
| Cell Survival | 1 | 2016 | 1003 | 0.100 |
Why?
|
| Microarray Analysis | 2 | 2011 | 95 | 0.100 |
Why?
|
| Radiation Tolerance | 1 | 2014 | 175 | 0.100 |
Why?
|
| Receptors, Notch | 1 | 2014 | 138 | 0.100 |
Why?
|
| Physicians | 1 | 2020 | 683 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 3837 | 0.100 |
Why?
|
| Adult | 4 | 2025 | 27949 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2016 | 1525 | 0.100 |
Why?
|
| Mice, Nude | 1 | 2014 | 824 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 1054 | 0.090 |
Why?
|
| Mice, Knockout | 1 | 2016 | 2122 | 0.090 |
Why?
|
| Phosphatidylethanolamine Binding Protein | 1 | 2011 | 35 | 0.090 |
Why?
|
| Mice | 4 | 2023 | 12239 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 2301 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2007 | 2020 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2543 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2014 | 1120 | 0.080 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 40 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2010 | 523 | 0.070 |
Why?
|
| Carcinogens | 1 | 2009 | 101 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 603 | 0.070 |
Why?
|
| Carcinoma | 1 | 2011 | 439 | 0.070 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 167 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2011 | 580 | 0.060 |
Why?
|
| Mitochondria | 1 | 2010 | 612 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2007 | 197 | 0.060 |
Why?
|
| Genomics | 2 | 2023 | 848 | 0.060 |
Why?
|
| Desmosomes | 1 | 2006 | 11 | 0.060 |
Why?
|
| Smoking Cessation | 1 | 2009 | 269 | 0.060 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 86 | 0.060 |
Why?
|
| Integrins | 1 | 2006 | 79 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 1 | 2007 | 1025 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 292 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 303 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 115 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 2017 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1790 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1932 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2017 | 1735 | 0.050 |
Why?
|
| Peritoneal Lavage | 1 | 2024 | 12 | 0.050 |
Why?
|
| Ascites | 1 | 2024 | 54 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2024 | 10185 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2006 | 729 | 0.050 |
Why?
|
| Workflow | 1 | 2023 | 78 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2024 | 266 | 0.050 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2023 | 7 | 0.050 |
Why?
|
| Umbilical Veins | 1 | 2003 | 45 | 0.050 |
Why?
|
| Thymine | 1 | 2003 | 17 | 0.050 |
Why?
|
| Indoles | 1 | 2024 | 301 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 48 | 0.050 |
Why?
|
| Workload | 1 | 2023 | 126 | 0.050 |
Why?
|
| COS Cells | 1 | 2003 | 163 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2003 | 103 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 3058 | 0.050 |
Why?
|
| Myofibroblasts | 1 | 2023 | 51 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2024 | 384 | 0.040 |
Why?
|
| Prognosis | 2 | 2024 | 3915 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2003 | 422 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2021 | 33 | 0.040 |
Why?
|
| Transfection | 1 | 2003 | 878 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2021 | 23 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.040 |
Why?
|
| Netherlands | 1 | 2020 | 25 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 64 | 0.040 |
Why?
|
| Carbamates | 1 | 2020 | 15 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 759 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 436 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 34 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 381 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 118 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 134 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2021 | 234 | 0.040 |
Why?
|
| Thiazoles | 1 | 2020 | 124 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 168 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 192 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 360 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2020 | 112 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2023 | 752 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2023 | 565 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 162 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2020 | 129 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1173 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2020 | 331 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2828 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 304 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 223 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 665 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 1913 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1715 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 379 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 504 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 402 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 920 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 156 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 98 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1171 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2718 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2466 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 1002 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 1584 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 2484 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2493 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 317 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 1061 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1769 | 0.010 |
Why?
|